Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 10,201	$ 8,417
Short-term investments		16,915
Accounts receivable	373	602
Inventories, net — current	9,416	1,794
Prepaid expenses and other current assets	1,204	712
Total current assets	21,194	28,440
Restricted cash	2,001
Property and equipment, net	3,484	1,799
Right of use asset	6,013	1,963
Inventories, net — noncurrent	461	364
Goodwill	301
Intangible assets, net	400
Other noncurrent assets	23	8
Total assets	33,877	32,574
Current liabilities:
Accounts payable and accrued expenses	6,711	4,685
Amounts due to related parties	29	40
Debt — current	705	24
Unearned revenue — current		42
Operating lease liability — current	700	611
Other current liabilities	263	306
Total current liabilities	8,408	5,708
Debt — noncurrent	2,548	107
Operating lease liability — noncurrent	5,574	1,497
Common stock warrant liabilities	3,065	14,936
Other noncurrent liabilities	2,280	2,000
Total liabilities	21,875	24,248
Commitments and contingencies (Note 14)
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 10,832,203 and 8,646,149 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	51	49
Additional paid-in capital	231,954	214,826
Accumulated other comprehensive income		1
Accumulated deficit	(220,725)	(207,171)
Total Arcadia Biosciences stockholders’ equity	11,280	7,705
Non-controlling interest	722	621
Total stockholders' equity	12,002	8,326
Total liabilities and stockholders’ equity	$ 33,877	$ 32,574